Table 1. Clinical characteristics of study population
Phenotype/covariateParticipants, N = 42
Gender
Female, no. (%)11 (26)
Male, no. (%)31 (74)
Age
Years, mean ± SD9.22 ± 4.5
1–4 years old, n (%)9 (21)
5–8 years old, n (%)9 (21)
9–14 years old, n (%)23 (57)
Signs or symptoms at enrollment
Days post‐symptom onset, mean ± SD1.41 ± 0.5
Fever, mean temperature ± SD, °C38.3 ± 0.8
Fever, mean duration ± SD, days2.4 ± 0.6
High fever, peak temperature > 38.5°C, n (%)16 (38)
Retroorbital pain, n (%)7 (16)
Osteomuscular pain, n (%)26 (62)
Rash, n (%)41 (98)
Arthralgia, n (%)36 (86)
Myalgia, n (%)20 (48)
Headache, n (%)9 (21)
Abdominal pain, n (%)13 (31)
Vomiting, n (%)4 (10)
Fluid accumulation, n (%)14 (33)
Hospitalized, n (%)36 (86)
Laboratory values at enrollment
Median platelet count, mm−3 (range)199,000 (88,000–337,000)
Nadir platelet count < 100,000 mm−3, n (%)8 (19)
Median white cell count, mm−3 (range)8,140 (3,030–16,120)
Median monocyte % of WBCs (range)8.9 (4.1–14.6)
Median lymphocyte % of WBCs (range)39.7 (10.4–66.4)
Laboratory values at convalescent timepoint
Days post‐symptom onset, mean ± SD15.7 ± 0.6
Median CHIKV Ab titer, dilutions (range)1,458 (232–7,794)
Severity categorizationa
More severe (%)21 (50)
Less severe (%)21 (50)
  • WBC, white blood cell; CHIKV, chikungunya virus; Ab, antibody.

  • a Cases were categorized as more severe if the patient had either a peak fever of >38.5°C or a nadir platelet count of < 100,000 mm−3.